


Atopic Dermatitis: A Heterogeneous Disease

Atopic dermatitis (AD) is a common, chronic, debilitating, fluctuating **inflammatory skin disease**. Patients with AD can experience a range of clinical symptoms, **including eczematous lesions, severe pruritus, inflammation, and dry skin**^{1,2}




The experience of AD can **vary significantly from patient to patient**. Age of onset, symptoms and comorbidities, lesional morphology and distribution, and severity of symptoms may vary among individuals^{1,3-6}




AD prevalence is affecting up to 10% of adults and 20% of children¹




Globally, more than 230 million people are estimated to suffer from AD¹



Patients with AD may present with different phenotypes⁶



CONTINUED >



Comorbidities and Mental Health in Patients With AD

- Patients with AD have a higher risk for developing other atopic diseases, including food allergies, asthma, and allergic rhinitis^{2,9,14,15}
- Data suggests that AD is associated with comorbidities including anemia, obesity, headaches, and an increase in cardiovascular risk factors^{2,3,9,16}
- Patients with AD are at higher risk of developing mental health disorders, including anxiety, depression, cognitive dysfunction, and suicidal ideation^{3,17}
- Children and adolescents with AD are at increased risk of developing mental health disorders, in particular depression, anxiety, and conduct disorders.⁸⁻¹⁰ This relationship is further exacerbated by sleep disturbances and disease severity.¹⁸ Investigations to determine if there is a link between AD and developmental disorders, such as attention-deficit/hyperactivity disorder and autism, are being conducted¹⁹

The Impact of Sleep Disturbance in AD

- Sleep disturbance is one of the major factors leading to impaired quality of life²⁰
- A majority of adults with AD have reported experiencing sleep disturbance²⁰
- The frequency and severity of sleep disturbance are worse with AD severity¹⁰
- Sleep disturbance can consequently lead to daytime sleepiness, fatigue, and impaired productivity at school or work²

References:

1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *Lancet*. 2020;396(10247):345-360. doi:10.1016/S0140-6736(20)31286-1
2. Ständer S. Atopic dermatitis. *N Engl J Med*. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911
3. Silverberg JI. Comorbidities and the impact of atopic dermatitis. *Ann Allergy Asthma Immunol*. 2019;123(2):144-151. doi:10.1016/j.anai.2019.04.020
4. Silverberg JI. Adult-onset atopic dermatitis. *J Allergy Clin Immunol Pract*. 2019;7(1):28-33. doi:10.1016/j.jaip.2018.09.029
5. Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology, and treatment. *Immunol Allergy Clin North Am*. 2015;35(1):161-183. doi:10.1016/j.iac.2014.09.008
6. Chovatiya R, Lei D, Ahmed A, Chavda R, Gabriel S, Silverberg JI. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. *Ann Allergy Asthma Immunol*. 2021;127(1): 83-90.e2. doi:10.1016/j.anai.2021.03.019
7. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. *J Invest Dermatol*. 2014;134(6):1527-1534. doi:10.1038/jid.2013.446
8. Bickers DR, Lim HW, Margolis D, et al; American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004: a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. *J Am Acad Dermatol*. 2006;55(3):490-500. doi:10.1016/j.jaad.2006.05.048
9. Avena-Woods C. Overview of atopic dermatitis. *Am J Manag Care*. 2017;23(8)(suppl):S115-S123
10. Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. *Clin Cosmet Invest Dermatol*. 2016;9:159-166. doi:10.2147/CCID.S91263
11. Lifschitz C. The impact of atopic dermatitis on quality of life. *Ann Nutr Metab*. 2015;66(suppl 1):34-40. doi:10.1159/000370226
12. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. *J Am Acad Dermatol*. 2017;77(2):274-279.e3. doi:10.1016/j.jaad.2017.04.019
13. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. *Ann Allergy Asthma Immunol*. 2018;121(3):340-347. doi:10.1016/j.anai.2018.07.006
14. Hahn EL, Bacharier LB. The atopic march: the pattern of allergic disease development in childhood. *Immunol Allergy Clin North Am*. 2005;25(2):231-246. doi:10.1016/j.iac.2005.02.004
15. Barberio G, Pajno GB, Vita D, Caminiti L, Canonica GW, Passalacqua G. Does a "reverse" atopic march exist? *Allergy*. 2008;63(12):1630-1632. doi:10.1111/j.1398-9995.2008.01710.x
16. Silverberg JI. Association between childhood eczema and headaches: an analysis of 19 US population-based studies. *J Allergy Clin Immunol*. 2016;137(2):492-499.e5. doi:10.1016/j.jaci.2015.07.020
17. Silverberg JI, Gelfand JM, Margolis DJ, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. *Br J Dermatol*. 2019;181(3):554-565. doi:10.1111/bjd.17683
18. Yaghaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2013;131(2):428-433. doi:10.1016/j.jaci.2012.10.041
19. Lee CY, Chen MH, Jeng MJ, et al. Longitudinal association between early atopic dermatitis and subsequent attention-deficit or autistic disorder: a population-based case-control study. *Medicine*. 2016;95(39):e5005. doi:10.1097/MD.0000000000005005
20. Jeon C, Yan D, Nakamura M, et al. Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review. *Derm Ther*. 2017;7(3):349-364. doi:10.1007/s13555-017-0192-3
21. Halvorsen JA, Lien L, Dalgard F, Bjertness E, Stern RS. Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. *J Invest Dermatol*. 2014;134(7):1847-1854. doi:10.1038/jid.2014.70
22. McCleary KK. Understanding the lived experience of eczema: the "voice of the patient" report on the eczema patient-focused drug development meeting. More Than Skin Deep Initiative. March 2020. Accessed June 22, 2022. http://www.morethanskindeep-eczema.org/uploads/1/2/5/3/125377765/mtsd_report_-_digital_file_1.pdf

GALDERMA

For healthcare professionals only.

©2022 Galderma Holding SA. All Rights Reserved.
All trademarks are the property of their respective owners.

GL-NAD-2200046 August 2022

